(Total Views: 611)
Posted On: 04/06/2020 6:46:50 PM
Post# of 149014
A Trial of -Lopinavir-Ritonavir (Kaletra)
https://www.nejm.org/doi/full/10.1056/NEJMoa2001282
CONCLUSIONS
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308. opens in new tab.)
Other Info
https://www.fiercepharma.com/pharma-asia/does...tudy-finds
https://www.nejm.org/doi/full/10.1056/NEJMoa2001282
CONCLUSIONS
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308. opens in new tab.)
Other Info
https://www.fiercepharma.com/pharma-asia/does...tudy-finds
(0)
(0)Scroll down for more posts â–¼
